Literature DB >> 1247882

Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system.

F Javoy, C Sotelo, A Herbet, Y Agid.   

Abstract

The neurotoxic specificity of injections of 6-hydroxydopamine (6-OHDA) into areas containing either dopamine (DA) cell bodies (substantia nigra) or DA axon terminals (striatum) was studied. This selective effect was compared to the unspecific effects of copper sulfate (CuSO4) injection and electrocoagulation. One to two days after unilateral nigral injection of 2 mug of either 6-OHDA or CuSO4 into the nigra the volume of the unspecific lesions around the tip of the cannula was very similar. Only the 6-OHDA-induced lesions were associated with elective degeneration of the nigral DA neurons. Ten days after the administration of the same compounds the gliosis in the substantia nigra was much more extensive in CuSO4-than in 6-OHDA-treated rats; however, the reduction of DA concentrations in the ipsilateral striatum was only noticeable after 6-OHDA (-62%). A somewhat similar decrease of striatal DA levels (-52%) was observed after large electrocoagulation of the substantia nigra. Ten days after 6-OHDA (8mug) or electrolytic lesion of the striatum the Km for DA, serotonin and choline uptakes were similar in the striata of both sides, suggesting that the uptake process in the non-damaged neurons of the lesioned side was functionally normal. Following electrolytic lesion of the striatum, serotonin and choline Vmax values were decreased to about the same extent as the striatal reduction in weight and DA levels. When directly administered into the striatum 6-OHDA also produced a decline in DA concentration and Vmax but in contrast did not affect serotonin and choline uptake (Vmax), suggesting that the drug specifically destroyed dopaminergic neurons. The present data confirm that selective DA denervation can be achieved when appropriate amounts of the drug are injected into brain tissue in order to limit the unspecific lesion.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1247882     DOI: 10.1016/0006-8993(76)90877-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  26 in total

1.  Partial selectivity of 6-OHDA induced neuronal degeneration after intraissular injection in the brain with special reference to the nigro-striatal dopamine system.

Authors:  F Javoy
Journal:  J Neural Transm       Date:  1975       Impact factor: 3.575

2.  Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease.

Authors:  Sofía Sánchez-Iglesias; Pablo Rey; Estefanía Méndez-Alvarez; José Luis Labandeira-García; Ramón Soto-Otero
Journal:  Neurochem Res       Date:  2006-12-12       Impact factor: 3.996

Review 3.  Parkinson's disease: what the model systems have taught us so far.

Authors:  Swagata Ghatak; Dorit Trudler; Nima Dolatabadi; Rajesh Ambasudhan
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

4.  Relationship between sensorimotor neglect and the specificity, degree and locus of mesotelencephalic dopaminergic cell loss following 6-hydroxydopamine.

Authors:  G J Lees; R R Kydd; J J Wright
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

5.  PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: old switch, new target.

Authors:  Abdullah Shafique Ahmad; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Neurotox Res       Date:  2013-02-06       Impact factor: 3.911

6.  Quantifying muscle alterations in a Parkinson's disease animal model using electromyographic biomarkers.

Authors:  Pablo Y Teruya; Fernando D Farfán; Álvaro G Pizá; Jorge H Soletta; Facundo A Lucianna; Ana L Albarracín
Journal:  Med Biol Eng Comput       Date:  2021-07-23       Impact factor: 2.602

7.  Presence of somatostatin or neurotensin in lateral septal dopaminergic axon terminals of distinct hypothalamic and midbrain origins: convergence on the somatospiny neurons.

Authors:  R L Jakab; C Leranth
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

8.  NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.

Authors:  Ana Clara Cristóvão; Subhrangshu Guhathakurta; Eugene Bok; Goun Je; Seung Don Yoo; Dong-Hee Choi; Yoon-Seong Kim
Journal:  J Neurosci       Date:  2012-10-17       Impact factor: 6.167

9.  A preliminary study on the behaviour and biochemical responses subsequent to the injection of 5,6-dihydroxytryptamine into the substantia nigra of the rat.

Authors:  N N Osborne; V Neuhoff; K H Sontag; S Wolfarth
Journal:  Experientia       Date:  1978-04-15

Review 10.  Animal models of Parkinson's disease progression.

Authors:  Gloria E Meredith; Patricia K Sonsalla; Marie-Francoise Chesselet
Journal:  Acta Neuropathol       Date:  2008-02-14       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.